Real-World Data Boost Santhera's Latest DMD Filing, And The Markets Agree

 
• By Jo Shorthouse

Despite being knocked back twice, Santhera CEO Thomas Meier is still confident Raxone has a place as a Duchenne muscular dystrophy therapy, and believes new long-term data will strengthen its third application to the EU in the coming months.

Dart
Could new data hit the bullseye? • Source: Shutterstock

More from Rare Diseases

More from Scrip